Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia

Resource type
Journal Article
Title
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
Abstract
In 760 patients with cancer in whom chemotherapy-induced neutropenia was expected to last more than seven days, those assigned to levofloxacin (500 mg daily) had a lower incidence of fever (65 percent vs. 85 percent) and clinically documented bacteremias than those assigned to placebo. The benefits of prophylaxis were similar in patients with acute leukemia and those with solid tumors or lymphoma. These data support the prophylactic use of levofloxacin in this high-risk population.
Publication
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Date
September 8, 2005
Volume
353
Issue
10
Pages
977-987
Accessed
12/6/20, 10:09 AM
PMID
16148283
ISSN
0028-4793
Library Catalog
Taylor and Francis+NEJM
Citation
Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Dionisi, M. S., Martinelli, G., Allione, B., D’Antonio, D., Buelli, M., Nosari, A. M., Cilloni, D., Zuffa, E., Cantaffa, R., Specchia, G., Amadori, S., Fabbiano, F., Deliliers, G. L., Lauria, F., Foà, R., & Del Favero, A. (2005). Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia. New England Journal of Medicine, 353(10), 977–987. https://doi.org/10.1056/NEJMoa044097
HEME-ONC AND CELLULAR THERAPIES